Adrenal steroid metabolites and bone status in patients with adrenal incidentalomas and hypercortisolism.
Adrenal incidentalomas
Autonomous cortisol secretion
Cortisol-producing adenomas
Steroid metabolites
Steroid-induced osteoporosis
Journal
EBioMedicine
ISSN: 2352-3964
Titre abrégé: EBioMedicine
Pays: Netherlands
ID NLM: 101647039
Informations de publication
Date de publication:
Sep 2023
Sep 2023
Historique:
received:
21
04
2023
revised:
13
07
2023
accepted:
13
07
2023
medline:
18
9
2023
pubmed:
6
8
2023
entrez:
5
8
2023
Statut:
ppublish
Résumé
Autonomous cortisol secretion (ACS), resulting from cortisol-producing adenomas (CPA), causes endogenous steroid-induced osteoporosis (SIOP). However, the risk of endogenous SIOP cannot be explained by cortisol excess alone, and how other steroid metabolites affect bone status is unclear. ACS was diagnosed as serum cortisol ≥1.8 μg/dL after the 1-mg dexamethasone suppression test (DST-cortisol). Using liquid chromatography tandem mass spectrometry, 21 plasma steroid metabolites were measured in 73 patients with ACS and 85 patients with non-functioning adrenal tumors (NFAT). Expression of steroidogenic enzymes and relevant steroid metabolites were analyzed in some of CPA tissues. Discriminant and principal component analyses distinguished steroid profiles between the ACS and NFAT groups in premenopausal women. Premenopausal women with ACS exhibited higher levels of a mineralocorticoid metabolite, 11-deoxycorticosterone (11-DOC), and lower levels of androgen metabolites, dehydroepiandrosterone-sulfate, and androsterone-glucuronide. In premenopausal women with ACS, DST-cortisol negatively correlated with trabecular bone score (TBS). Additionally, 11-DOC negatively correlated with lumbar spine-bone mineral density, whereas androsterone-glucuronide positively correlated with TBS. The CPA tissues showed increased 11-DOC levels with increased expression of CYP21A2, essential for 11-DOC synthesis. Adrenal non-tumor tissues were atrophied with reduced expression of CYB5A, required for androgen synthesis. This study demonstrates that unbalanced production of adrenal steroid metabolites, derived from both adrenal tumor and non-tumor tissues, contributes to the pathogenesis of endogenous SIOP in premenopausal women with ACS. JSPS KAKENHI, Secom Science and Technology Foundation, Takeda Science Foundation, Japan Foundation for Applied Enzymology, AMED-CREST, JSTA-STEP, JST-Moonshot, and Ono Medical Research Foundation.
Sections du résumé
BACKGROUND
BACKGROUND
Autonomous cortisol secretion (ACS), resulting from cortisol-producing adenomas (CPA), causes endogenous steroid-induced osteoporosis (SIOP). However, the risk of endogenous SIOP cannot be explained by cortisol excess alone, and how other steroid metabolites affect bone status is unclear.
METHODS
METHODS
ACS was diagnosed as serum cortisol ≥1.8 μg/dL after the 1-mg dexamethasone suppression test (DST-cortisol). Using liquid chromatography tandem mass spectrometry, 21 plasma steroid metabolites were measured in 73 patients with ACS and 85 patients with non-functioning adrenal tumors (NFAT). Expression of steroidogenic enzymes and relevant steroid metabolites were analyzed in some of CPA tissues.
FINDINGS
RESULTS
Discriminant and principal component analyses distinguished steroid profiles between the ACS and NFAT groups in premenopausal women. Premenopausal women with ACS exhibited higher levels of a mineralocorticoid metabolite, 11-deoxycorticosterone (11-DOC), and lower levels of androgen metabolites, dehydroepiandrosterone-sulfate, and androsterone-glucuronide. In premenopausal women with ACS, DST-cortisol negatively correlated with trabecular bone score (TBS). Additionally, 11-DOC negatively correlated with lumbar spine-bone mineral density, whereas androsterone-glucuronide positively correlated with TBS. The CPA tissues showed increased 11-DOC levels with increased expression of CYP21A2, essential for 11-DOC synthesis. Adrenal non-tumor tissues were atrophied with reduced expression of CYB5A, required for androgen synthesis.
INTERPRETATION
CONCLUSIONS
This study demonstrates that unbalanced production of adrenal steroid metabolites, derived from both adrenal tumor and non-tumor tissues, contributes to the pathogenesis of endogenous SIOP in premenopausal women with ACS.
FUNDING
BACKGROUND
JSPS KAKENHI, Secom Science and Technology Foundation, Takeda Science Foundation, Japan Foundation for Applied Enzymology, AMED-CREST, JSTA-STEP, JST-Moonshot, and Ono Medical Research Foundation.
Identifiants
pubmed: 37543511
pii: S2352-3964(23)00298-0
doi: 10.1016/j.ebiom.2023.104733
pmc: PMC10505782
pii:
doi:
Substances chimiques
Hydrocortisone
WI4X0X7BPJ
Androgens
0
Androsterone
C24W7J5D5R
Glucuronides
0
Steroids
0
CYP21A2 protein, human
EC 1.14.14.16
Steroid 21-Hydroxylase
EC 1.14.14.16
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
104733Informations de copyright
Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of interests The authors have declared that no conflicts of interest exist.
Références
Eur J Endocrinol. 2007 Sep;157(3):359-66
pubmed: 17766720
J Clin Endocrinol Metab. 2022 Feb 17;107(3):e1181-e1192
pubmed: 34665854
PLoS One. 2019 Mar 29;14(3):e0214549
pubmed: 30925175
Osteoporos Int. 2005 Mar;16 Suppl 2:S3-7
pubmed: 15365697
Eur J Endocrinol. 2016 Aug;175(2):G1-G34
pubmed: 27390021
J Steroid Biochem Mol Biol. 2021 Sep;212:105924
pubmed: 34089832
Best Pract Res Clin Endocrinol Metab. 2021 Jan;35(1):101488
pubmed: 33589355
Osteoporos Int. 2019 May;30(5):1059-1069
pubmed: 30719548
Metabolites. 2022 Jul 24;12(8):
pubmed: 35893245
Lancet Diabetes Endocrinol. 2022 Jul;10(7):499-508
pubmed: 35533704
Environ Health. 2018 Aug 20;17(1):67
pubmed: 30126431
J Clin Endocrinol Metab. 2021 Jan 23;106(2):e638-e649
pubmed: 33053159
J Clin Endocrinol Metab. 2010 Jun;95(6):2630-3
pubmed: 20525913
Clin Chem. 2018 Mar;64(3):586-596
pubmed: 29208661
Biostatistics. 2015 Jul;16(3):493-508
pubmed: 25532525
Eur J Endocrinol. 2023 Apr 4;188(4):343-352
pubmed: 36952249
J Clin Endocrinol Metab. 2008 May;93(5):1526-40
pubmed: 18334580
Osteoporos Int. 2018 Oct;29(10):2299-2307
pubmed: 29971455
J Clin Endocrinol Metab. 2017 Mar 1;102(3):840-848
pubmed: 27901631
J Clin Endocrinol Metab. 2006 May;91(5):1779-84
pubmed: 16522701
J Bone Miner Res. 2011 Aug;26(8):1816-21
pubmed: 21472775
J Cachexia Sarcopenia Muscle. 2020 Jun;11(3):698-709
pubmed: 32017473
J Steroid Biochem Mol Biol. 2006 Jun;99(4-5):182-8
pubmed: 16621522
Mol Cell Endocrinol. 2006 Mar 27;248(1-2):79-86
pubmed: 16337083
Horm Res. 2004;62 Suppl 3:110-4
pubmed: 15539809
Drug Test Anal. 2021 Mar;13(3):550-557
pubmed: 33142032
Endocr Rev. 2018 Oct 1;39(5):519-548
pubmed: 29905835
J Clin Endocrinol Metab. 2019 Oct 1;104(10):4331-4340
pubmed: 30977834
J Bone Miner Res. 2012 Oct;27(10):2223-30
pubmed: 22549969
J Bone Miner Metab. 2013 May;31(3):247-57
pubmed: 23553500
J Clin Endocrinol Metab. 1993 Apr;76(4):918-23
pubmed: 8473406
Clin Endocrinol (Oxf). 2013 Jul;79(1):1-11
pubmed: 23452135
J Clin Endocrinol Metab. 2019 Nov 1;104(11):5519-5528
pubmed: 31381072
Maturitas. 2020 Nov;141:33-38
pubmed: 33036700
Osteoporos Int. 2013 Nov;24(11):2801-7
pubmed: 23695421
Nucleic Acids Res. 2021 Jul 2;49(W1):W388-W396
pubmed: 34019663
Osteoporos Int. 2019 Jan;30(1):3-44
pubmed: 30324412
Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42
pubmed: 27662240
J Clin Endocrinol Metab. 2015 Sep;100(9):3529-38
pubmed: 26161451
Osteoporos Int. 2004 Nov;15(11):855-61
pubmed: 15034643
BMC Endocr Disord. 2017 May 19;17(1):26
pubmed: 28525998
Diabetes Care. 2020 Feb;43(2):405-410
pubmed: 31727688
Circulation. 2005 Feb 22;111(7):871-8
pubmed: 15710759
J Clin Endocrinol Metab. 2019 Aug 1;104(8):3545-3556
pubmed: 30896752
J Clin Endocrinol Metab. 2021 Oct 21;106(11):e4580-e4592
pubmed: 34415029
Endocr Rev. 2020 Dec 1;41(6):
pubmed: 32266384
Front Endocrinol (Lausanne). 2019 Feb 07;10:54
pubmed: 30792695
J Am Coll Cardiol. 2008 Jul 8;52(2):135-8
pubmed: 18598893
Endocrinol Jpn. 1985 Oct;32(5):691-700
pubmed: 2936600
J Clin Endocrinol Metab. 2009 Sep;94(9):3207-14
pubmed: 19549741
Eur J Endocrinol. 2002 Jun;146(6):789-99
pubmed: 12039699
Am J Physiol. 1996 Apr;270(4 Pt 1):C1088-95
pubmed: 8928736
Clin Endocrinol (Oxf). 2018 Aug;89(2):148-154
pubmed: 29781519
Clin Endocrinol (Oxf). 2020 Mar;92(3):206-213
pubmed: 31868939
Bone. 2021 Jan;142:115607
pubmed: 32829039
J Bone Miner Res. 2001 Aug;16(8):1496-504
pubmed: 11499872
Lancet. 2015 Aug 29;386(9996):913-27
pubmed: 26004339
Biochem Biophys Res Commun. 2014 May 9;447(3):407-12
pubmed: 24713303
Mayo Clin Proc. 2003 Oct;78(10):1257-73
pubmed: 14531485